SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

RBC Capital Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $134

RBC Capital maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $135 to $134.

Benzinga · -

RBC Capital maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $135 to $134.